MoonLake Immunotherapeutics
MLTX
MLTX
83 hedge funds and large institutions have $2.86B invested in MoonLake Immunotherapeutics in 2023 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
93% more funds holding
Funds holding: 43 → 83 (+40)
27.75% more ownership
Funds ownership: 100.69% → 128.44% (+28%)
Holders
83
Holding in Top 10
10
Calls
–
Puts
–
Top Buyers
| 1 | +$78.1M | |
| 2 | +$46.4M | |
| 3 | +$33.6M | |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$30.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.9M |
Top Sellers
| 1 | -$24.3M | |
| 2 | -$7.98M | |
| 3 | -$5.95M | |
| 4 |
Axa
Paris,
France
|
-$3.94M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.45M |